Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation – Business Wire
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation Business Wire
Month: May 2025
Zepbound helps users lose more weight than Wegovy, new trial reveals
GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation – BioSpace
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation BioSpace
Semaglutide Therapy Improves Liver Histology in MASH
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis. Medscape Medical News
Weight loss drugs may cut cancer risk by 50% according to ‘transformational’ new study
New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more effective than getting weight loss surgery.
Eli Lilly’s Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more…
New study compares Wegovy and Zepbound for the first time
For the first time, a study in The New England Journal of Medicine is comparing the most popular drugs for weight loss, Zepbound and Wegovy. NBC News medical contributor Dr. Natalie Azar joins TODAY to break down the results and the differences in the medications.
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink Partners said confirm the GLP-1 drug’s edge in the closely watched market race.
Zepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about … Read more
Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovy
Eli Lilly said Sunday that new data on Zepbound show the GIP/GLP-1 dual agonist is a better weight loss drug than Novo Nordisk’s Wegovy. Almost 65% of obese or overweight people treated with Zepbound in …